GLP-1 therapies are reshaping metabolic care at unprecedented speed — but alongside the headlines, clinicians are left navigating complex questions around long-term outcomes, sustainability, nutrition, and patient dependency.
This thought-leadership evening brings healthcare professionals together to explore how GLP-1s fit into modern metabolic care — without losing sight of physiology, behaviour, and long-term health.
We are delighted to welcome Dr David Unwin as our keynote speaker — a GP, internationally recognised educator, and one of the most trusted clinical voices in metabolic health. Known for his measured, evidence-led approach, Dr Unwin will explore how GLP-1 therapies can be used thoughtfully and responsibly, alongside nutrition-first strategies that protect metabolic resilience, muscle mass, and patient autonomy.
Rather than positioning GLP-1s as a silver bullet — or dismissing them outright — this keynote will challenge clinicians to think critically, ethically, and systemically about where these therapies belong in practice.
Keynote Speaker
Dr David Unwin
GP | International Leader in Metabolic Health
Dr Unwin is widely recognised for his balanced, evidence-based approach to metabolic care. In this keynote, he will explore where GLP-1 therapies sit within modern clinical practice, how nutrition remains foundational, and what sustainable metabolic care looks like beyond short-term interventions.
Spotlight Speaker
Lorna Driver-Davies
Clinical Nutritionist | Wild Nutrition
Session details:
Redefining GLP-1 for Women's Health
Clinical Immuno-Endocrine Applications in Gynaecology
Lorna will forward the compelling concept of the future of immuno-gynaecology, positioning GLP-1 as a sophisticated immunomodulatory tool and hormone modulator with profound implications for women’s health. Beyond glycemic control and weight management, GLP-1 interrupts the cycle of chronic, low-grade inflammation and reduces pro-inflammatory adipokines to offer targeted clinical benefits across gynaecological diseases, conditions, and lifestages. This presentation explores how the systemic regulatory effects of GLP-1 redefine its role from a simple metabolic aid to a crucial intervention for the complex female immune and endocrine landscape.
Spotlight Speaker
Lesley Harper
Registered Nutritional Therapist | Invivo
Session details:
When GLP-1 Meets the Gut
Beyond Glycaemic Control: Navigating Gastrointestinal Effects in Clinical Practice
In this presentation, Lesley examines the gastrointestinal implications of GLP-1 agonist therapies, positioning the gut as a central mediator of both therapeutic benefit and clinical complexity. Moving beyond appetite regulation and glycaemic control, she explores how GLP-1 medications influence bile flow, gut barrier integrity and microbial ecology — key determinants of digestive and systemic health. This session outlines common gastrointestinal presentations associated with GLP-1 use and provides a mechanistic framework for understanding their underlying drivers. It also considers practical strategies to mitigate digestive disruption and explores how endogenous GLP-1 production may be supported naturally through targeted nutritional and lifestyle interventions.
Spotlight Speaker
Christine Bailey
Award-Winning Nutritionist | Doctor's Data
Session details:
GLP-1 and the Gut: What Stool Testing Reveals About Microbial Shifts and Digestive Function
Christine will explore how GLP-1 therapies influence gut physiology, and microbial ecology, highlighting the complex shifts that can occur within the gastrointestinal environment during treatment. Moving beyond appetite regulation and glycaemic control, Christine examines emerging research on microbial diversity and key gut health markers, including changes in butyrate-producing bacteria and Akkermansia abundance - that may signal dysbiotic responses to sustained GLP-1 signalling.
Using insights from the Doctor's Data GI360 stool test, Christine will outline the markers practitioners should pay particular attention to when working with clients using GLP-1 medications. This session offers a practical framework for interpreting gut microbiome data in this evolving clinical context, and highlights why functional stool testing can play a meaningful role in monitoring gastrointestinal resilience and guiding personalised nutritional support.
Panel Discussion
Following the keynote, an expert panel will broaden the conversation by examining:
-
Alternatives and adjuncts to GLP-1 therapies
-
Nutrition-first approaches to metabolic health
-
Long-term sustainability and patient independence
-
Practical considerations clinicians face in real-world practice
Whats included:
- Access to full event + Q&A
- Bowl food, Snacks, Drinks, and Networking
- Exclusive Sponsor Discounts and goodybag
The evening will then open into an expert panel discussion, bringing together diverse clinical perspectives to explore alternatives, adjuncts, and nutrition-led strategies that support metabolic health beyond pharmacology alone. Together, we’ll examine what sustainable metabolic care really looks like — and how practitioners can design pathways that serve patients long after the prescription ends.
This is not a debate for headlines.
It’s a clinical conversation for clinicians and practitioners shaping the future of metabolic care.
